SYNACT.ST STO
SynAct Pharma AB
1W: +2.9%
1M: +2.1%
3M: -7.8%
YTD: -13.6%
1Y: -3.5%
3Y: -82.2%
5Y: -83.8%
kr 17.80 ($1.77)
+0.62 (+3.61%)
Weekly Expected Move ±6.3%
kr 16
kr 17
kr 18
kr 19
kr 20
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+100.0% ▲
Operating Income
-$117M
-30.2% ▼
Net Income
-$111M
-34.5% ▼
EPS (Diluted)
$-2.17
-4.3% ▼
EBITDA
-$117M
-660.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $88K | $1M | $778K | $617K | $0 |
| Gross Profit | -$88K | -$1M | -$778K | -$617K | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $60M | $70M | $105M | $49M | $86M |
| SG&A Expenses | $16M | $36M | $34M | $40M | $32M |
| Operating Expenses | $77M | $106M | $224M | $90M | $117M |
| Operating Income | -$77M | -$106M | -$224M | -$90M | -$117M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $105K | $294K | $797K | $820K | $2M |
| Income Before Tax | -$77M | -$107M | -$224M | -$91M | -$119M |
| Tax Expense | -$8M | -$8M | -$8M | -$8M | -$8M |
| Net Income | -$69M | -$99M | -$216M | -$82M | -$111M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-2.67 | $-3.60 | $-6.64 | $-2.08 | $-2.17 |
| EBITDA | -$77M | -$106M | -$223M | -$15M | -$117M |
| Shares Outstanding | 26M | 28M | 33M | 40M | 51M |